Cases & Deals

Ysios Capital and strategic investor invest in Kala Pharmaceuticals

Clients Ysios Capital Partners and strategic investor

Jones Day represented Ysios Capital Partners and a strategic investor in connection with their investment in a $22.5 million private placement of Series B Preferred Stock by Kala Pharmaceuticals, Inc., a leading developer of innovative products that enhance penetration of therapeutic agents into ocular tissue based on Kala’s proprietary Mucus Penetrating Particle technology.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.